Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Lineage Cell Therapeutics Inc (LCTX)

0.95   0.013 (1.43%) 10-01 15:40
Open: 0.93 Pre. Close: 0.9366
High: 0.9699 Low: 0.9251
Volume: 435,457 Market Cap: 142M
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company is headquartered in Carlsbad, California and currently employs 76 full-time employees. The firm is focused on developing cell therapies. The company programs are based on its cell-based therapy platform. The company is focused on developing treatments for conditions, including age-related degenerative diseases and other serious medical conditions. Its pipeline includes OpRegen, OPC1 and VAC2. OpRegen product candidate is a cell replacement therapy. OpRegen is comprised of retinal pigment epithelium cells and is being tested for the treatment of advanced dry age-related macular degeneration (dry AMD) with geographic atrophy. OPC1 is a cell replacement therapy comprised of oligodendrocyte progenitor cells. OPC1 is being developed for the treatment of acute spinal cord injuries (SCI). VAC2 is an allogeneic cancer immunotherapy comprised of mature, antigen-presenting dendritic cells. VAC2 is being developed for non-small cell lung cancer (NSCLC).

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.961 - 0.966 0.966 - 0.97
Low: 0.909 - 0.914 0.914 - 0.918
Close: 0.933 - 0.941 0.941 - 0.947

Technical analysis

as of: 2020-10-01 3:06:18 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 1.20     One year: 1.33
Support: Support1: 0.84    Support2: 0.70
Resistance: Resistance1: 1.03    Resistance2: 1.14
Pivot: 0.96
Moving Average: MA(5): 0.94     MA(20): 0.94
MA(100): 0.91     MA(250): 0.90
MACD: MACD(12,26): 0.01     Signal(9): 0.02
Stochastic oscillator: %K(14,3): 30.24     %D(3): 29.46
RSI: RSI(14): 51.80
52-week: High: 1.67  Low: 0.53  Change(%): -2.9
Average Vol(K): 3-Month: 67722  10-Days: 65908

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
LCTX has closed above bottom band by 45.2%. Bollinger Bands are 4.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Tue, 29 Sep 2020
Lineage Cell Therapeutics: Meet the ‘hidden gem" cell therapy specialist with three clinical stage assets - Proactive Investors USA & Canada

Tue, 29 Sep 2020
Newgioco Group, Lineage Cell Therapeutics and Killi set to take stage at Proactive"s One2One virtual investor forum - Proactive Investors USA & Canada

Fri, 25 Sep 2020
Why Lineage Cell Therapeutics Inc. (LCTX)’s Most Recent Report Reveals Some Hints About Its Future -

Fri, 25 Sep 2020
Reasons Why Long-term Faith on Lineage Cell Therapeutics Inc. (LCTX) Could Pay Off Investors - The InvestChronicle

Mon, 21 Sep 2020
Lineage Cell Therapeutics Inc (LCTX) Stock: Buy, Hold, or Sell? - InvestorsObserver

Thu, 17 Sep 2020
Lineage Cell Therapeutics to Present at FORCE Wealth Virtual Fireside Chat on September 23, 2020 - Business Wire

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  AMEX
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 150
Shares Float (M) 108
% Held by Insiders 5.97
% Held by Institutions 42.33
Shares Short (K) 7,770
Shares Short P. Month (K) 8,770

Stock Financials

EPS -0.373
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 0.780
Profit Margin
Operating Margin -1014.29
Return on Assets (ttm) -13.0
Return on Equity (ttm) -44.8
Qtrly Rev. Growth -44.6
Gross Profit (p.s.) 0.021
Sales Per Share 0.021
EBITDA (p.s.) -0.190
Qtrly Earnings Growth
Operating Cash Flow (M) -28
Levered Free Cash Flow (M) -39

Stock Valuations

PE Ratio -2.55
PEG Ratio
Price to Book value 1.22
Price to Sales 45.97
Price to Cash Flow -5.15

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.